Cytosorbents Corp (NASDAQ:CTSO) traded up 0.3% during trading on Monday . The stock traded as high as $7.10 and last traded at $7.05, 3,117 shares traded hands during mid-day trading. A decline of 97% from the average session volume of 106,325 shares. The stock had previously closed at $7.03.

Several research analysts have commented on the company. ValuEngine raised VESTAS WIND SYS/ADR from a “hold” rating to a “buy” rating in a research report on Thursday, May 9th. Maxim Group set a $7.00 price objective on Eagle Bulk Shipping and gave the stock a “buy” rating in a report on Wednesday, May 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Cytosorbents presently has a consensus rating of “Hold” and a consensus price target of $14.67.

The stock has a market capitalization of $227.36 million, a P/E ratio of -12.95 and a beta of 1.50. The firm has a fifty day moving average of $6.56. The company has a current ratio of 3.70, a quick ratio of 3.52 and a debt-to-equity ratio of 0.62.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings data on Tuesday, May 7th. The medical research company reported ($0.15) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.03. Cytosorbents had a negative return on equity of 103.90% and a negative net margin of 83.93%. The company had revenue of $5.19 million for the quarter, compared to analyst estimates of $6.03 million. As a group, sell-side analysts expect that Cytosorbents Corp will post -0.56 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the company. Rhumbline Advisers lifted its holdings in Cytosorbents by 54.8% during the fourth quarter. Rhumbline Advisers now owns 38,135 shares of the medical research company’s stock valued at $308,000 after purchasing an additional 13,505 shares in the last quarter. BlackRock Inc. raised its position in shares of Cytosorbents by 1.2% in the fourth quarter. BlackRock Inc. now owns 1,985,640 shares of the medical research company’s stock valued at $16,046,000 after buying an additional 23,891 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Cytosorbents by 2.7% in the fourth quarter. Bank of New York Mellon Corp now owns 97,330 shares of the medical research company’s stock valued at $786,000 after buying an additional 2,516 shares during the last quarter. Raymond James & Associates raised its position in shares of Cytosorbents by 13.1% in the fourth quarter. Raymond James & Associates now owns 168,800 shares of the medical research company’s stock valued at $1,364,000 after buying an additional 19,500 shares during the last quarter. Finally, Advisor Group Inc. raised its position in shares of Cytosorbents by 13.2% in the fourth quarter. Advisor Group Inc. now owns 27,161 shares of the medical research company’s stock valued at $219,000 after buying an additional 3,160 shares during the last quarter. 26.39% of the stock is currently owned by institutional investors.

About Cytosorbents (NASDAQ:CTSO)

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.

Featured Article: Momentum Indicators

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.